drugset / Trial / NCT04056897
Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
International multicenter, randomized, double-blind, double-masked, placebo-controlled study of efficacy and safety of BCD-132 (JSC BIOСAD, Russia) using an active reference drug (teriflunomide) for the treatment of patients with multiple sclerosis
Timeline
- Start
- 2019-06-07
- Primary completion
- 2020-07-13
- Completion
- 2022-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCD-132 | Monoclonal antibody | 125 mg | Intravenous |
| Subject | BCD-132 | Monoclonal antibody | 500 mg | Intravenous |
| Comparator | Teriflunomide | Small molecule | 14 mg | Oral |